<DOC>
	<DOCNO>NCT00781716</DOCNO>
	<brief_summary>This study compare clinical effect CYPHER® stent ENDEAVOR® stent patient acute ST elevation myocardial infarction . It also aim analyze current status emergency PCI green channel ( time take door→ hospital→ PIC sign-off→ needle→ balloon ) patient ST elevation myocardial infarction China .</brief_summary>
	<brief_title>Safety Efficacy Study CYPHER® Sirolimus Stent ENDEAVOR® Zotarolimus Stent Patients With Acute ST Elevation Myocardial Infarction ( STEMI ) Analysis Current Status Emergency PCI Green Channel STEMI Patients China</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Emergencies</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . The patient must ≥18 year ≤75 age . 2 . Prolonged , continuous ( ≥ 30 min ) chest pain despite nitrate : ( 1 ) STsegment elevation ≥ least 2 lead , reciprocal STsegment elevation ≥ 0.05mv precordial lead STsegment elevation ≥ 0.01mv , ( 2 ) newly develop leave bundle branch block 3 . Symptoms ≥ 30 min ≤12 hour 4 . The patient consent participate authorize collection release medical information sign `` Patient Informed Consent Form '' 5 . All lesion require intervention one native coronary artery amendable implantation one Cypher® SirolimusEluting Coronary Stent System Endeavor® ZotarolimusEluting Coronary Stent 6 . The patient guardian willing able cooperate study procedure require follow visit . 1 . Pregnant breastfeed female female childbearing potential , possibly plan become pregnant time enrollment study . 2 . Systemic ( intravenous ) Sirolimus use within 12 month . 3 . Patients hypersensitivity allergies one drug component indicate Instructions Use either stent . 4 . History bleed diathesis know coagulopathy ( include heparininduced thrombocytopenia ) , refuse blood transfusion . 5 . Gastrointestinal genitourinary bleeding within prior 3 month , major surgery within 2 month . 6 . Current platelet count &lt; 100 x 10^9cells/L Hgb &lt; 10 g/dL . 7 . Fibrinolytic therapy current MI treatment 8 . Previous coronary intervention target vessel postCABG vessel disease 9 . Transplant patient 10 . Patients EF &lt; 25 % 11 . Patients cardiogenic shock ; life expectancy short 12 month 12 . Severe kidney dysfunction : Creatinine level ≥2.0mg/dL dependence dialysis . 13 . Severe hepatic dysfunction ( AST ALT ≥ 3 time upper normal reference value ) . 14 . The patient currently , CRESTMI Study , participate another investigational device drug study clinically interfere CRESTMI study endpoint ; require coronary angiography coronary artery imaging procedure . The patient may enrol CRESTMI Study . 15 . Severe tortuous calcify vessel ; stent difficulty go ; blood vessel diameter small minimum stent diameter available ; patient unsuitable stent implantation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>ST elevation myocardial infarction</keyword>
	<keyword>Drug elute stent</keyword>
</DOC>